Seminars in thrombosis and hemostasis最新文献

筛选
英文 中文
Mortality from Pulmonary Embolism in Patients with Post-Coronavirus Disease Syndrome. 冠状病毒后疾病综合征患者肺栓塞死亡率
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-03-28 DOI: 10.1055/a-2552-1829
Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J Favaloro
{"title":"Mortality from Pulmonary Embolism in Patients with Post-Coronavirus Disease Syndrome.","authors":"Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J Favaloro","doi":"10.1055/a-2552-1829","DOIUrl":"10.1055/a-2552-1829","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"838-840"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous Thromboembolism Occurrence and Association with Gastrointestinal Disorders in Children with Cystic Fibrosis: An Analysis from the TriNetX Research Network Global Multicenter Real-World Dataset. 囊性纤维化儿童静脉血栓栓塞的发生及其与胃肠道疾病的关联:来自TriNetX研究网络全球多中心真实世界数据集的分析
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-01-13 DOI: 10.1055/s-0044-1801825
Carolena Trocchia, Dina Ashour, Maua Mosha, Bailey Hamner, Marisol Betensky, Neil Goldenberg, Racha Khalaf
{"title":"Venous Thromboembolism Occurrence and Association with Gastrointestinal Disorders in Children with Cystic Fibrosis: An Analysis from the TriNetX Research Network Global Multicenter Real-World Dataset.","authors":"Carolena Trocchia, Dina Ashour, Maua Mosha, Bailey Hamner, Marisol Betensky, Neil Goldenberg, Racha Khalaf","doi":"10.1055/s-0044-1801825","DOIUrl":"10.1055/s-0044-1801825","url":null,"abstract":"<p><p>The purpose of this study is to (1) estimate and compare the prevalence of venous thromboembolism (VTE) in children (age 0 to ≤21) with versus without cystic fibrosis (CF); (2) investigate putative associations between specific gastrointestinal (GI) manifestations and the development of VTE among children with CF. This was a multicenter case-control analysis among patients aged 0 to ≤ 21 years between 2010 and 2020, using the TriNetX Research Network. Data queries included ICD-9/10 (International Classification of Diseases-9th/10th Revision) diagnosis codes. Bivariate associations with VTE among CF patients were compared using Chi-square testing for categorical variables and Student's <i>t</i>-test for continuous variables. We used multivariable logistic regression to test for independent associations of GI manifestations with VTE among children with CF, with adjustment for other salient covariates. There was a total of 7,689 children with and 22,327,660 without CF. The frequency of occurrence of VTE was increased nearly 20-fold among those with, as compared with without CF (130 vs. 7 per 10,000 patients). Acute pancreatitis (adjusted odd ratio [aOR] = 3.80, [95% confidence interval, CI: 2.00-7.22]), biliary disease (aOR = 2.17 [95% CI: 1.17-4.03]), gastrostomy status (aOR = 2.01 [95% CI: 1.27-3.18]), and malabsorption/malnutrition (aOR = 2.41 [95% CI: 1.52-3.82]) were each associated with a higher likelihood of VTE among children with CF. In conclusion, we found a significantly increased frequency of VTE occurrence and association of specific GI diseases as independent risk factors for VTE among children with CF compared with those without.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"736-744"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulants in Children with Renal Impairment: A Narrative Review. 儿童肾脏损害的抗凝治疗:一个叙述性的回顾。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-03-28 DOI: 10.1055/a-2546-0126
Amy L Kiskaddon, Daniel M Witt, Marisol Betensky, Anthony A Sochet, Amanda Memken, Christoph Male, Neil A Goldenberg
{"title":"Anticoagulants in Children with Renal Impairment: A Narrative Review.","authors":"Amy L Kiskaddon, Daniel M Witt, Marisol Betensky, Anthony A Sochet, Amanda Memken, Christoph Male, Neil A Goldenberg","doi":"10.1055/a-2546-0126","DOIUrl":"10.1055/a-2546-0126","url":null,"abstract":"<p><p>Venous thromboembolism is a common cause of morbidity and mortality in children with renal disease. To properly treat and prevent thromboembolism in this patient population, it is important to be familiar with the multitude of anticoagulant agents currently available. Many anticoagulant drugs undergo some extent of renal elimination. There are important considerations for the selection, dosing, and monitoring of anticoagulant drugs for patients with renal impairment due to various pharmacokinetic alterations that may occur. While there are data to help guide dosing and monitoring in adults, evidence regarding renal dose adjustment of many anticoagulant drugs in children are limited. For the clinician, anticoagulation management in children with renal impairment presents unique challenges. In addition to considering overall bleeding risk, the extent of renal impairment may vary by patient, making a one-size-fits-all approach to managing these patients difficult. These factors, combined with limited data, can make managing anticoagulation in children with renal impairment a challenge. Therefore, the focus of this review will be to describe the pharmacokinetics of the following anticoagulants in children with impaired renal function: unfractionated heparin, enoxaparin, dalteparin, rivaroxaban, apixaban, edoxaban, fondaparinux, bivalirudin, argatroban, dabigatran, and warfarin.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"776-787"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoagulation: The R-VTE-predict and MACE-predict Risk Scores. 停止抗凝治疗后静脉血栓栓塞和动脉心血管事件复发的预测:r - vte预测和mace预测风险评分
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-04-09 DOI: 10.1055/s-0045-1807262
Steve R Noumegni, Benjamin Espinasse, Romain Didier, Raphael Le Mao, Claire De Moreuil, Cécile Tromeur, Emmanuelle Le Moigne, Pierre-Yves Le Roux, Francis Couturaud
{"title":"Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoagulation: The R-VTE-predict and MACE-predict Risk Scores.","authors":"Steve R Noumegni, Benjamin Espinasse, Romain Didier, Raphael Le Mao, Claire De Moreuil, Cécile Tromeur, Emmanuelle Le Moigne, Pierre-Yves Le Roux, Francis Couturaud","doi":"10.1055/s-0045-1807262","DOIUrl":"10.1055/s-0045-1807262","url":null,"abstract":"<p><p>Patients who had venous thromboembolism (VTE) are not only at increased risk of recurrent VTE but also of major adverse cardiovascular events (MACEs) than the general population. Therefore, the prediction of the risk of these events is important for a tailored prevention and mitigation strategy. We aimed to develop simple scores to estimate recurrent VTE and MACE risks after the discontinuation of anticoagulation in a large cohort of individuals who suffered VTE (EDITH cohort). The primary endpoints were recurrent symptomatic VTE and MACE (composite of non-fatal acute coronary syndrome, stroke and cardiovascular death). Arterial thrombotic event (ATE) exclusively was also considered. Independent predictors of main outcomes were derived from multivariable Cox regression models. Weighted integer points based on the effect estimate of identified predictors were used to derive the final risk scores. A total of 1,999 participants (mean age: 54.78 years, 46.4% male, 43.6% unprovoked VTE) were included in the derivation cohort and 10,000 in the validation cohort (built using bootstrapping). During a median post-anticoagulation follow-up of 6.9 years, recurrent VTE occurred in 29.5% of participants and MACE in 14.8%. Independent predictors of recurrent VTE were male sex, age >65 years, cancer-associated VTE, and unprovoked VTE (vs. transient risk factor-associated VTE). Independent predictors of MACE were age >65 years, cancer-associated VTE, hypertension, renal insufficiency, and atrial fibrillation. The risk of recurrent VTE (moderate vs. low: hazard ratio [HR]: 2.62, 95% confidence interval [CI]: 2.06-3.34; high vs. low: HR: 3.78, 95% CI: 2.91-4.89), MACE (moderate vs. low: HR: 6.37, 95% CI: 3.19-12.69; high vs. low: HR: 12.32, 95% CI: 6.09-24.89), and ATE (based on MACE-predict risk score) increased gradually from the lowest to highest of the respective prediction risk score groups. These results were confirmed in the validation cohort with overall reasonable models' discrimination performance (recurrent VTE C-statistic: 0.62-0.63, MACE and ATE C-statistic: 0.72-0.77). Contemporary simple risk scores based on readily available clinical characteristics can reasonably predict the risk of recurrent VTE and MACE after the discontinuation of anticoagulation. These findings may influence the choice of anticoagulation strategy after the acute phase of VTE and, therefore, need confirmation by further studies.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"788-799"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a) and Cerebral Venous Sinus Thrombosis: A Case and the Evidence. 脂蛋白(a)与脑静脉窦血栓形成:1例及证据。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-05-23 DOI: 10.1055/a-2601-9261
Anthony R Sandre, Ali Panju, Sonia S Anand
{"title":"Lipoprotein(a) and Cerebral Venous Sinus Thrombosis: A Case and the Evidence.","authors":"Anthony R Sandre, Ali Panju, Sonia S Anand","doi":"10.1055/a-2601-9261","DOIUrl":"10.1055/a-2601-9261","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"834-837"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nebulized Heparin in 2025: at the Interface between Promising Benefits and the Need for Further Research. 2025年雾化肝素:在前景看好和需要进一步研究之间的界面。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-03-06 DOI: 10.1055/a-2552-1886
Giuseppe Lippi, Emmanuel J Favaloro
{"title":"Nebulized Heparin in 2025: at the Interface between Promising Benefits and the Need for Further Research.","authors":"Giuseppe Lippi, Emmanuel J Favaloro","doi":"10.1055/a-2552-1886","DOIUrl":"10.1055/a-2552-1886","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"826-828"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Thrombosis and Hemostasis-Part XII. 血栓和止血的最新进展——第十二部分。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-09-12 DOI: 10.1055/s-0045-1809697
Sam Schulman
{"title":"Recent Advances in Thrombosis and Hemostasis-Part XII.","authors":"Sam Schulman","doi":"10.1055/s-0045-1809697","DOIUrl":"https://doi.org/10.1055/s-0045-1809697","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":"51 7","pages":"721-723"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145055729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetic Resonance Screening for Cerebral Venous Sinus Thrombosis during Treatment with Pegaspargase. Pegaspargase治疗期间脑静脉窦血栓的磁共振筛查。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-10-01 Epub Date: 2025-04-25 DOI: 10.1055/a-2575-7359
Xiao Zhang, Yang Fu, Hongsheng Wang, Xiaohua Zhu, Yi Yu, Junye Jiang, Ping Cao, Xiaowen Qian, Chen Shen, Xiaowen Zhai
{"title":"Magnetic Resonance Screening for Cerebral Venous Sinus Thrombosis during Treatment with Pegaspargase.","authors":"Xiao Zhang, Yang Fu, Hongsheng Wang, Xiaohua Zhu, Yi Yu, Junye Jiang, Ping Cao, Xiaowen Qian, Chen Shen, Xiaowen Zhai","doi":"10.1055/a-2575-7359","DOIUrl":"10.1055/a-2575-7359","url":null,"abstract":"<p><p>In children with leukemia, cerebral venous sinus thrombosis (CVST) has a significant incidence and mortality rate, which may interfere with the chemotherapy process and lead to long-term neurological complications. However, large studies and population-based data on CVST in children are scarce. This study aims to characterize pediatric CVST associated with pegaspargase (PEG-ASP) and evaluate the significance of magnetic resonance venography (MRV) screening following induction remission in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). We present a retrospective cohort of a total of 27 children with CSVT and ALL/LBL. The study covers a 4-year period for MRV screening following induction remission and an 8-year comparison period, involving 716 children treated at the Department of Hematology, Children's Hospital of Fudan University. The detection rate of CVST significantly increased after MRV screening (8.4% vs. 1.6%, <i>p</i> < 0.01). Over half (58%) of the CVST cases were asymptomatic. Male (84% vs. 52%, <i>p</i> = 0.008), immune subtype of T (37% vs. 10%, <i>p</i> = 0.001) and higher initial platelet counts (196.25 ± 140.67 vs. 112.49 ± 115.62, <i>p</i> = 0.02) patients were more likely to develop CVST. The common symptoms were headache (56%), seizures (31%), vomiting (13%), lethargy (13%), coma (6%), hallucinations (6%), and schizophrenia (6%). Symptomatic patients had a higher likelihood of transverse sinus involvement (75% vs. 9%, <i>p</i> = 0.006). Asymptomatic patients had shorter treatment durations (25.5 ± 16.7 weeks vs. 51.6 ± 25.8 weeks, <i>p</i> = 0.02) and fewer long-term complications (50% vs. 0%, <i>p</i> = 0.02). Thromboelastographic amplitude values at 30 minutes after maximum amplitude were significantly higher in symptomatic patients (49.4 ± 13.2 vs. 35.1 ± 8.3, <i>p</i> = 0.01). This study highlights a significant incidence of PEG-ASP-related CVST in children, with MRV screening revealing a notably higher detection rate than previously reported. Most cases were asymptomatic, which demonstrated better prognoses, emphasizing the importance of MRV for early CVST diagnosis after induction remission in ALL/LBL.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"818-825"},"PeriodicalIF":4.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Lupus Anticoagulant Detection in Heparinized Patients: An Automated Heparin-Resistant Recalcifying Solution. 改善肝素化患者狼疮抗凝血检测:一种自动肝素耐药重钙化溶液。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-09-26 DOI: 10.1055/a-2701-0113
Agathe Herb, Nathan Drouin, Amélie Rist, Jordan Wimmer, Laurent Mauvieux, Laurent Sattler
{"title":"Improving Lupus Anticoagulant Detection in Heparinized Patients: An Automated Heparin-Resistant Recalcifying Solution.","authors":"Agathe Herb, Nathan Drouin, Amélie Rist, Jordan Wimmer, Laurent Mauvieux, Laurent Sattler","doi":"10.1055/a-2701-0113","DOIUrl":"https://doi.org/10.1055/a-2701-0113","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145178043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness. Emicizumab治疗获得性血友病A:出血控制、安全性和成本效益。
IF 4.1 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-09-09 DOI: 10.1055/a-2691-6232
Gerard Gurumurthy, Lianna Reynolds, Martin Scott, Elizabeth Davies, Charles Hay, Jecko Thachil
{"title":"Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness.","authors":"Gerard Gurumurthy, Lianna Reynolds, Martin Scott, Elizabeth Davies, Charles Hay, Jecko Thachil","doi":"10.1055/a-2691-6232","DOIUrl":"https://doi.org/10.1055/a-2691-6232","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信